Feb 2024

Celix Pharma announces the launch of Dimethyl Fumarate GR Capsules 

Celix Pharma is pleased to announce the launch of Dimethyl Fumarate Gastro-resistant hard capsules, on day 1 post expiry of the marketing exclusivity for Tecfidera® in the UK. Dimethyl fumarate 120mg, 240mg GR capsules are supplied in blister packs containing 14 or 56 capsules. 

Dimethyl fumarate GR capsules are indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).  

Although its exact mechanism of action is not fully known, dimethyl fumarate is thought to modulate the immune response to be less inflammatory and may have antioxidant properties that could be 

protective against damage to the brain and spinal cord (1). 

Commenting on this launch, Subir Kohli, Co-founder & CEO said, “It’s fantastic to add another Day 1 launch to our portfolio of products for the hospital / specialty channel. Dimethyl fumarate is available from hospital pharmacy and directly to patients via a homecare service offering. Launch of a generic dimethyl fumarate will bring significant savings to the NHS, which spends in excess of £150mn on this therapy (2).” 

Shantreddy, Co-founder & COO, expressed his satisfaction with the successful launch of dimethyl fumarate GR capsules. He said, “This is the result of a strong partnership with our development / manufacturing partner, who helped us deliver this product on day 1. We are proud to offer this affordable and effective treatment option for patients with RRMS.”

Source:

1 https://www.nationalmssociety.org/Treating-MS/Medications/Dimethyl-Fumarate-Delayed-Release-Capsules

2 NHSBSA published figures